OligoMedic is a privately held Canadian company created in 2010 and focused on developing and commercializing medical devices.

OligoMedic's founders are biomaterials experts who have developed several devices for the orthopedic market.

OligoMedic's technology is based on injectable thermosensitive hydrogels (thermogels) that are room-temperature liquids that solidify at body-temperature.

OligoMedic's leading product JointRep™ is CE-marked, and patented and granted in all major countries.

JointRep™ is presently distributed to the orthopedic market to repair cartilage, with spectacular success in over 1700 patients.

JointRep™ can also be used to deliver platelet rich plasma (PRPs) or adipose derived mesenchymal cells for various orthopedic applications such as tendon and meniscus treatment.

Controlled post-market clinical study for use of JointRep™ in grade III-IV knee cartilage lesions showed exceptional results in terms of pain reduction and mobility improvement for patients, and MRI evidence of hyaline cartilage regrowth.

Don’t Replace, JointRep™ Preserves and Repairs

JointRep™ is an injectable implant. It is the first product to provide a minimally invasive curative treatment for traumatic or arthrosis cartilage defects of any size or grade. Most existing treatments at best alleviate pain and delay the progression of cartilage loss. Other less desirable alternatives include total joint replacement.

Controlled Post-market Clinical Study (Italy)

conducted by Dr. Gennaro Pipino, professor of orthopedic surgery at the University of Lugano, (Switzerland) and head of the department of orthopaedics and traumatology at the Villa Regina Hospital, Bologna (Italy).

Dr. Pipino led the 60-patient study to evaluate the treatment efficacy of microfracture combined with JointRep™ in repairing cartilage lesions and improving patient clinical symptoms.  The control group was treated with microfracture alone, which is the current standard of care in cartilage repair in both Europe and United States.

The study was conducted on patients with grade III-IV cartilage lesions in knee joints, who were considered for total knee replacement (prosthesis). The patients were aged between 18 and 75. Importantly, the rehabilitation time is 8 weeks for microfracture but only 2 weeks for the combined treatment.

Under local anaesthesia, the test group was treated through standard arthroscopic procedure, adding JointRep™ to the condyle site after marrow stimulation. Patients were discharged on the same day and allowed isometrics, lateral extensions, and total load ambulation with the aid of a contralateral crutch during the first five days. The patients subsequently began physiotherapy (leg extensions, swimming and stationary bike).

The 6-month clinical results showed that the JointRep™ treated-cohort provided spectacular clinical symptom reduction, achieving more than clear statistical significance over the microfracture-alone control group.  At 6 months, the arthroscopic JointRep™ treatment was successful in reducing the WOMAC (Western Ontario and McMaster Universities Arthritis Index) pain and stiffness scores and increasing the WOMAC physical and mobility scores. The total WOMAC score improved on average by a staggering 88% (compared to 40% for the control group). The results were comparable in every age category.

From a scientific standpoint, these clinical results suggest that the JointRep™ scaffold provides a very fertile environment for chondrogenesis. It is believed that lipocytes, platelets and growth-factors migrate within the JointRep™ gel scaffold to enhance the differentiation of stem cells released by the microfractures. This hypothesis is strongly supported by MRI scans with T2 suppression performed on the test group patients after 6 months, which showed identical signature for the treated area and the pre-existing healthy cartilage, indicating the presence of type II collagen in the regenerated cartilage.

It’s worth emphasizing the dramatic reduction of economic costs associated with osteoarthritis provided by JointRep™. The operation lasts no more than a half hour, the patient is released on the same day, and the rehabilitation time is much shorter than for the microfracture treatment without JointRep™.

Schematic procedure of the treatment

The lesion can be of any size or shape.

Some key points about JointRep™


How JointRep looks less than a minute after it's implanted in cartilage void.

  • JointRep™ is a thermosensitive hydrogel that rapidly solidifies when heated to body temperature.
  • Unlike a viscosupplement, JointRep™ directly repairs affected cartilage.
  • Exceptional pain reduction and mobility improvement when combined with microfracture.
  • No technical hurdles: JointRep™ should be stored between 2 and 8°C, but can be transported at ambient temperature.
  • Can be used without planning. Preparation time is between 3 and 5 minutes, enabling the physician to use it ad-hoc if defects are noticed in the course of a routine arthroscopic inspection or treatment (a study of over 30,000 arthroscopies in the United States has revealed an average of 2.7 defects in 63% of patients).
  • JointRep™ is currently not licenced for sale in the USA and Canada.

Video Gallery

Arthroscopic lavage/debridement operation with JointRep™

This procedure is used to treat less severe chondropathies like symptomatic grade I-II osteoarthritis. There is no cartilage regrowth but lasting pain relief after 2-3 months. The age limit is 55.

With Dr. Nicolas Duval, Orthopedist

Standard Arthroscopic operation (Lavage/debridement)

Preparation and injection of JointRep™ implant

Arthroscopic JointRep™ operation with microfracture

This procedure is used to treat more severe chondropathies like grade III-IV osteoarthritis. The rehab period is very short, the pain relief is very quick and there is genuine regrowth of hyaline cartilage. The age limit is 75.

With Dr. Gennaro Pipino, full professor of orthopedic surgery, University of Lugano (Switzerland)

View from the operation room

Operation screen

Total weight ambulation with contralateral cane

90 minutes after the operation.

Demo: mixing JointRep™ components


One month after knee osteoarthritis treatment with microfracture + JointRep™.

A happy patient's post to Facebook three weeks after his microfracture + JointRep™.

News and Updates

Other clinical trials on different indications are planned and will be disclosed when protocols are defined. Planning formal clinical trials for intervertebral disc regeneration using JointRep™ mixed with autologous stem cells.


Preliminary steps taken toward procedures with FDA for market approval in the US.


European clinical controlled-trial: 60 patients, and comparing microfracture to microfracture & JointRep™ at different times. Prof. Gennaro Pipino, as Principal Investigator, is a full professor of orthopaedic surgery, at the University of Lugano in Switzerland and Director of Orthopaedic Surgery at the Villa Regina Hospital in Bologna, Italy. First study results will be published during Winter-2016.


Gaining market penetration in Europe, ANZ regions, Middle East, South East Asia, Central and South America including Brazil.


Initial experimentation with JointRep™ and microfracture. Results are highly favorable with fast pain relief, accelerated recovery time, and nice cartilage regrowth, as shown in these arthroscopic pictures:

From left to right:

Defect in intercondylar notch prepared for JointRep™.   Defect filled with material.  Defect one year after.
1.Healthy cartilage 2.Defect.

We succeeded in premixing JointRep™ with platelet rich plasma (PRP) while maintaining all the product's properties. The same can be done with bone marrow extract. This opens the possibility of using JointRep™ to deliver PRP or adipose derived mesenchymal cells for various orthopedic applications such as tendon and meniscus treatment.


Video showing the mixing of B1 and B2 first, then the mixing of (B1+B2) with approximately 1 cc of PRP (or less) and finally the mixing of (B1+B2+ PRP) and A giving an injectable gel that solidifies with temperature as does JointRep™ alone.


Video showing the mixing of B1 and B2 first, then the mixing of (B1+B2) with approximately 1 cc of bone marrow extract (or less) and finally the mixing of (B1+B2+ PRP) and A giving an injectable gel that solidifies with temperature as does JointRep™ alone.

Management Team


Dr. Amine Selmani, PhD President/CEO


Dr. Abdelatif Chenite, PhD CTO


Dr. Cyril Chaput, PhD, MBA VP  RA/QA


Mrs. Monique Jarry VP Finance & Corporate Development


Dr. Yves De Backer VP Europe & Other Countries Markets


Marwane Berrada VP Business Development, North American Markets


Sam Alexandre Selmani VP Marketing

Contact us

Don’t hes­i­tate to con­tact us for any enquiries you might have.

500 Cartier Blvd. № 113, Laval

(+1) 450-680-3371


Your Name (required)

Your Email (required)


Your Message